ChinaNet Online Holdings, Inc. (CNET) Reaches $4.80 After 6.00% Down Move; Nomura Asset Management Company LTD Has Lifted Pfizer (PFE) Position By $6.14 Million

January 14, 2018 - By Dolores Ford

The stock of ChinaNet Online Holdings, Inc. (NASDAQ:CNET) is a huge mover today! The stock decreased 24.76% or $1.58 during the last trading session, reaching $4.8. About 7.54M shares traded or 168.48% up from the average. ChinaNet Online Holdings, Inc. (NASDAQ:CNET) has declined 15.56% since January 14, 2017 and is downtrending. It has underperformed by 32.26% the S&P500.The move comes after 9 months negative chart setup for the $59.23 million company. It was reported on Jan, 14 by Barchart.com. We have $4.51 PT which if reached, will make NASDAQ:CNET worth $3.55M less.

Nomura Asset Management Company Ltd increased Pfizer Inc (PFE) stake by 16.52% reported in 2017Q3 SEC filing. Nomura Asset Management Company Ltd acquired 175,429 shares as Pfizer Inc (PFE)’s stock declined 3.45%. The Nomura Asset Management Company Ltd holds 1.24M shares with $44.18 million value, up from 1.06M last quarter. Pfizer Inc now has $217.80B valuation. The stock decreased 0.05% or $0.02 during the last trading session, reaching $36.54. About 19.20M shares traded or 25.61% up from the average. Pfizer Inc. (NYSE:PFE) has declined 2.76% since January 14, 2017 and is downtrending. It has underperformed by 19.46% the S&P500.

ChinaNet Online Holdings, Inc., through its subsidiaries, operates an integrated service platform that provides advertising and marketing services in the PeopleÂ’s Republic of China. The company has market cap of $59.23 million. The Company’s platform comprises CloundX, an omni-channel advertising and marketing system; and a data analysis management system. It currently has negative earnings. The firm offers Internet advertising, precision marketing, and related value added services through its Internet advertising portals, including 28.com; liansuo.com; zhifuwang.cn; and wp28.com.

Nomura Asset Management Company Ltd decreased Ishares Tr (MBB) stake by 3,500 shares to 11,900 valued at $1.27M in 2017Q3. It also reduced Fedex Corp (NYSE:FDX) stake by 80,963 shares and now owns 113,875 shares. Macerich Co (NYSE:MAC) was reduced too.

Since August 4, 2017, it had 0 insider purchases, and 10 selling transactions for $16.36 million activity. $249,900 worth of Pfizer Inc. (NYSE:PFE) was sold by MACKENZIE ALEXANDER R on Friday, September 1. Another trade for 94,409 shares valued at $3.21M was sold by DAMELIO FRANK A. $296,560 worth of Pfizer Inc. (NYSE:PFE) shares were sold by JOHNSON RADY A. READ IAN C sold 96,950 shares worth $3.30 million. $1.34M worth of stock was sold by SUSMAN SALLY on Tuesday, September 12. 8,064 shares valued at $263,693 were sold by OLSON LAURIE J on Monday, August 21.

Among 21 analysts covering Pfizer (NYSE:PFE), 9 have Buy rating, 1 Sell and 11 Hold. Therefore 43% are positive. Pfizer had 67 analyst reports since July 29, 2015 according to SRatingsIntel. On Thursday, April 7 the stock rating was maintained by Jefferies with “Buy”. As per Thursday, April 7, the company rating was reinitiated by JP Morgan. BMO Capital Markets maintained the shares of PFE in report on Friday, December 15 with “Buy” rating. The firm earned “Hold” rating on Monday, October 16 by Jefferies. The firm earned “Neutral” rating on Thursday, July 20 by Credit Suisse. The rating was maintained by Jefferies with “Buy” on Tuesday, June 14. The stock of Pfizer Inc. (NYSE:PFE) earned “Equal-Weight” rating by Barclays Capital on Tuesday, December 1. BMO Capital Markets maintained the shares of PFE in report on Monday, June 12 with “Hold” rating. On Thursday, July 13 the stock rating was maintained by Jefferies with “Hold”. The firm has “Hold” rating by BMO Capital Markets given on Tuesday, August 1.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>